Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia by Yedjou, Clement et al.
ORIGINAL ARTICLEadi2_22 59..65
Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity
Against Acute Promyelocytic Leukemia
Clement Yedjou, PhD, Laurette Thuisseu, BS, Christine Tchounwou, HS, Maria Gomes, MS,
Carolyn Howard, PhD, and Paul Tchounwou, ScD
Cellomics and Toxicogenomics Research Laboratory, NIH-Center for Environmental Health, College of Science,
Engineering and Technology, Jackson State University, Jackson, MS, USA
DOI: 10.1111/j.1753-5174.2009.00022.x
ABSTRACT
Introduction. Acute promyelocytic leukemia (APL) is a malignant disorder of the white blood cells. Arsenic trioxide
(As2O3) has been used as a therapeutic agent to treat APL and other tumors. Studies suggest that ascorbic acid (AA)
supplementation may improve the clinical outcome of As2O3 for APL patients. Our aim was to use human leukemia
(HL-60) APL-cells as an in vitro test model to evaluate the effect of physiologic doses of AA on As2O3-induced
toxicity and apoptosis of HL-60 cells.
Methods. HL-60 cells were treated either with a pharmacologic dose of As2O3 alone and with several physiologic
doses of AA. Cell survival was determined by trypan blue exclusion test. The extent of oxidative cell/tissue damage
was determined by measuring lipid hydroperoxide concentration by spectrophotometry. Cell apoptosis was measured
by ﬂow cytometry using Annexin-V and propidium iodide (PI) staining.
Results. AA treatment potentiates the cytotoxicity of As2O3 in HL-60 cells. Viability decreased from (58  3)% in
cells with As2O3 alone to (47  2)% in cells treated with 100 mM AA and 6 mg/mL As2O3 with P < 0.05. There was
a signiﬁcant (P < 0.05) increase in lipid hydroperoxide concentrations in HL-60 cells co-treated with AA compared
to As2O3 alone. Flow cytometry assessment (Annexin V FITC/PI) suggested that AA co-treatment induces more
apoptosis of HL-60 cells than did As2O3 alone, but this was not statistically signiﬁcant. Taken together, our
experiment indicates that As2O3 induced in vitro cell death and apoptosis of HL-60 cells. Administration of
physiologic doses of AA enhanced As2O3-induced cytotoxicity, oxidative cell/tissue damage, and apoptosis of HL-60
cells through externalization of phosphatidylserine.
Conclusions. These suggest that AA may enhance the cytotoxicity of As2O3, suggesting a possible future role of
AA/As2O3 combination therapy in patients with APL.
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I. Introduction
A
cute promyelocytic leukemia (APL) is a
malignant disorder of the white blood cells
which can affect patients of all ages. Arsenic triox-
ide (As2O3) is been used as a therapeutic agent to
treat APL [1] and other tumors [2]. In 2000, the
U.S. Food and Drug Administration (FDA)
approved the use of As2O3 (Trisenox) to treat
relapsed APL [3]. In vitro studies have shown that
As2O3 exerts a dual dose-dependent effect on APL
cells by inducing partial differentiation at low con-
centrations and apoptosis at high concentrations
[4,5]. Recently, we reported that the pharmaco-
logical effect of As2O3 as an effective anti-cancer
drug is associated with its cytotoxic and genotoxic
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Current research in our laboratory indicates that
As2O3 induces transcription of speciﬁc genes that
affect mitogen response, cell cycle progression,
programmed cell death, and cellular function in
many ways in cultured human leukemia (HL-60)
cells. Among these cellular responses to As2O3 in
human leukemia (HL-60) cells are up-regulation
of p53 tumor suppressor protein and repression of
the c-fos transcription factor involved in cell cycle
arrest or apoptosis, activation of cyclin D1 and
cyclin A involved in cell cycle progression [8].
Other studies indicate that As2O3 induces the gen-
eration of reactive oxygen species that contribute
signiﬁcantly to cell killing [2,9,10] promotion of
differentiation, and inhibition of growth [6].
As2O3 has also been used effectively in combi-
nation with other chemotherapeutic agents such as
all-trans retinoic acid to treat APL [11]. Ascorbic
acid (AA) is a natural supplement in our diet that
has been studied for the prevention of human
cancer and improvement of human health [12].
For many years, some scientists have claimed that
use of high doses of ascorbic acid (>10 g/day) cure
infections with common cold and treat AA can be
used to treat cancers diseases because of the effect
on the immune system [13]. Others researchers
have reported that AA is effective in the prevention
of cancer and protection against DNA damage
through the neutralization of free radicals [14,15].
They also reported that AA may act as a pro-
oxidant that helps the body’s own free radical
defense mechanism destroy tumors in their early
stages [15,16]. Several recent studies have pro-
vided evidence that AA may extend the therapeutic
spectrum of As2O3 in APL patients [17] and mul-
tiple myeloma patients [18]. However, little is
known about the mechanisms of action of AA
when combined with As2O3 for the treatment of
APL. Therefore, the aim of this research was to
use human leukemia (HL-60) APL-cells as an in
vitro test model to determine the potential mecha-
nism of action of AA on As2O3 chemotherapy of
APL.
II. Materials and Methods
Chemicals andTest Media
Arsenic trioxide (As2O3), CASRN 1327-53-3, MW
197.84, with an active ingredient of 100% (w/v)
arsenic in 10% nitric acid was purchased from
Fisher Scientiﬁc in (Houston Texas). Growth
medium RPMI 1640 containing 1 mmol/L L-
glutamine was purchased from Gibco BRL prod-
ucts (Grand Island, NY). Fetal bovine serum
(FBS), ascorbic acid, phosphate buffered saline
(PBS), and MTT assay kit were obtained from
Sigma Chemical Company (St. Louis, MO). Lipid
peroxidation kit was purchased from Calbiochem-
Novabiochem (San Diego, CA).
Tissue Culture
Human leukemia (HL-60) APL-cells, purchased
from the American Type Culture Collection
-ATCC (Manassas, VA), was thawed by gentle agi-
tation of their containers (vials) for 2 minutes in a
water bath at 37°C. After thawing, the content
of each vial of cell was transferred to a 25 cm
2
tissue culture ﬂask, diluted with up to 10mL of
RPMI 1640 containing 1 mmol/L L-glutamine
(GIBCO/BRL, Gaithersburg, MD) and supple-
mented with 10% (v/v) fetal bovine serum (FBS),
and 1% (w/v) penicillin/streptomycin. The 25 cm
2
culture ﬂasks, each containing 2 ¥ 10
6 viable cells,
were observed under the microscope, followed by
incubation in a humidiﬁed 5% CO2 incubator at
37°C. Three times a week, they were diluted under
same conditions to maintain a density of 5 ¥ 10
5/
mL, and harvested in the exponential phase of
growth. The cell viability was assessed by the
trypan blue exclusion test (Life Technologies) and
manually counted using a hemocytometer.
Treatment and Measurement of CellViability
In a recently published experiment, we reported
that physiologic doses of As2O3 increased cellular
proliferation while pharmacologic doses of As2O3
were highly cytotoxic to HL-60 cells, showing a 24
hours LD50 of 6.4  0.6 mg/mL [6]. Hence, to
examine the effect of ascorbic acid (AA) on As2O3-
induced cytotoxicity, cells exposed to physiologic
doses of AA (25, 50, and 100 mM) 30 minutes prior
were treated with 6 mg/mL As2O3 and incubated
in humidiﬁed 5% CO2 incubator at 37°C for 24
hours. After the treatment period, the cell viability
of human leukemia (HL-60) cells was determined
by standard live-dead staining. To this end, ten ml
of a 0.5% solution of the dye (trypan blue) was
added to 100 mL of treated cells (1.0 ¥ 10
5/mL).
The number of viable (transparent) and dead
(blue) cells was examined on a light microscopic
analysis.
Measurement of Lipid Hydroperoxide
Lipid peroxidation is traditionally quantiﬁed
by measuring malondialdehyde and 4-
hydroxynonenal. These assays are nonspeciﬁc and
60 Yedjou et al.
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A new lipid hydroperoxide assay kit [Calbiochem-
Novabiochem, San Diego, CA] was used in this
study to measure the hydroperoxide concentration
by directly using the redox reactions with ferrous
ions. The extraction procedure and measurement
of the extracted lipid hydroperoxides was per-
formed according to the manufacturer’s instruc-
tions (Calbiochem-Novabiochem, San Diego, CA)
[19,20].
Brieﬂy, untreated and treated HL-60 cells were
washed twice with cold PBS and counted for the
assay. A total volume of 20 ¥ 10
6 cells/mL in cold
PBS were mixed with 3 mL of chloroform/
methanol (2:1) solution, vortexed and mixed well.
The sample was centrifuged at 1000 ¥ g for 5
minutes at 0°C until phase separation was
achieved. The pasteur pipet was used carefully to
collect 700 mL of chloroform layer in the bottom
of the test tube and transferred to another test
tube. Freshly prepared chromogen (50 mL) was
added to each test tube, vortexed and mixed well.
The sample was incubated at room temperature
for 5 minutes. The absorbance of the sample was
monitored at 500 nm, and the concentration of
lipid hydroperoxide was determined from a stan-
dard curve.
AnnexinV FITC/PI Binding Assay by Flow Cytometry
The response of HL-60 cells to arsenic trioxide
(As2O3) alone and ascorbic acid (AA) plus As2O3
was assessed by ﬂow cytometry using Annexin V
FITC/PI staining kit. After 24 hours of exposure
to either a pharmacologic dose of As2O3, or differ-
ent physiologic doses of AA plus a pharmacologic
dose of As2O3,1¥ 10
6 cells/mL were washed in
PBS, re-suspended in binding buffer (10 mm
Hepes/NaOH pH 7.4, 140 mm NaCl, 2.5 mM
CaCl2), and stained with FITC-conjugated
annexin V (Pharmingen, Becton Dickinson Co.,
San Diego, CA, USA). Then, cells were incubated
for 15 minutes in the dark at room temperature,
washed with binding buffer and analysed by ﬂow
cytometry (FACS Calibar; Becton-Dickinson)
using CellQuest software.
Statistical Analysis
Experiments were performed at least in triplicates.
Data were represented as means  SDs. Where
appropriate, one-way anova test or Student paired
t-test was performed using SAS Software available
in the Bio-statistics Core Laboratory at Jackson
State University. P values less than 0.05 were con-
sidered statistically signiﬁcant.
III. Results
Ascorbic Acid Enhances the Cytotoxicity of Arsenic
Trioxide in HL-60 Cells
In the present study, HL-60 cells were treated
either with a pharmacologic dose of As2O3, or with
various physiologic doses of AA plus As2O3 as
described in the trypan blue exclusion test. As
shown in (Figure 1), As2O3 is highly cytotoxic
to HL-60 cells at 6 mg/mL of exposure. Co-
treatment of these cells using physiologic concen-
trations (25–100 mM) of AA and a pharmacologic
dose (6 mg/mL) of As2O3 resulted in a higher level
of cell death than did As2O3 alone. We found that
the viability of HL-60 cells declined from
(58  3)% in cells treated with As2O3 alone to
(47  2)% in cells treated with 100 mMA Aa n d
6 mg/mL As2O3 with P < 0.05.
Ascorbic Acid Enhances Lipid Hydroperoxide
Generation in ArsenicTrioxide-treated HL-60 Cells
A high level of lipid hydroperoxide concentra-
tion was detected in HL-60 cells after 24 hours
of As2O3 treatment compared to control cells
(Figure 2). A concentration-dependent increase in
lipid hydroperoxide generation was observed in
HL-60 cells co-treated with ascorbic acid (AA) and
As2O3 compared to As2O3 alone. Taken together,
co-administration of AA and As2O3 in culture cells
caused signiﬁcant (P < 0.05) increase of lipid
hydroperoxide concentration resulting from oxi-
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Figure 1 Potential effect of co-administration of ascorbic
acid (AA) and arsenic trioxide (As2O3) to human leukemia
(HL-60) cells. HL-60 cells were cultured in the absence or
presence of AA and As2O3 or in combination of AA and
As2O3 for 24 hr as indicated in the Materials and Methods.
Cell viability was determined based on the trypan blue
exclusion test. Each point represents a mean value and
standard deviation of 3 experiments with 6 replicates per
dose. *Signiﬁcantly different from the control by ANOVA Dun-
nett’s test; P < 0.05. **Signiﬁcantly different from As2O3
alone by ANOVA Dunnett’s test; P < 0.05.
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of poly-unsaturated fatty acids. Findings from this
experiment suggest that the pro-oxidant property
of AA in vitro may increase reactive oxygen species
(ROS) formation that potentiates the cytotoxicity
of As2O3.
Ascorbic Acid Enhances ArsenicTrioxide-induced
Apoptosis in HL-60 Cells
To determine whether physiologic doses of ascor-
bic acid (AA) could sensitize arsenic trioxide
(As2O3)-mediated apoptosis, HL-60 cells were
treated for 24 hours, subsequently stained with
annexin V/PI, and analyzed by ﬂow cytometry. As
shown in (Figures 3 and 4), AA enhanced the per-
centage of cells positive for annexin V, but this was
not statistical signiﬁcant. The percentage of cells
positive for annexin V was (40  5)% in cells
treated with As2O3 alone and (46  4)% in those
treated with 100 mM AA and 6 mg/mL As2O3 with
P > 0.05.
IV. Discussion
Ascorbic Acid Enhances the Cytotoxicity of Arsenic
Trioxide in HL-60 Cells
In this study, we investigated the cellular effect of
ascorbic acid (AA) in conjunction with arsenic tri-
oxide (As2O3) in human leukemia (HL-60) cells.
Our data showed increased cell death in the human
leukemia (HL-60) cells at physiologic doses (25–
100 mM) of AA and pharmacologic dose (6 mg/mL)
of As2O3, indicating potentiation effect between
AA and As2O3. We found that the combination of
physiologicdosesofAAandpharmacologicdoseof
As2O3 is more cytotoxic to HL-60 cells compared
to As2O3 alone. We previously demonstrated that
low or physiologic doses (25–100 mM) of AA were
not cytotoxic, suggesting that AA has the potential
to be safe and acts as effective chemosensitizing
agent in As2O3-based chemotherapy [21]. Zhang
and his co-workers have reported the role of physi-
ologic doses of AA in gastric cancer cells [22].
PreclinicalstudieshaveshowntheefﬁcacyofAs2O3
on various cultured human (HL-60, HepG2,
Jurkat) cancer cell lines [7]. Current research has
reported many possible treatments for APL
patients [23,24]. However, a common treatment
remains As2O3, or perhaps a combination of AA
and As2O3 [18]. Interestingly, ﬁnding from our
present studies suggest that the combination of
these two compounds could be a more proﬁcient
treatmentinkillingcancercellscomparedtoAs2O3
alone. Similar to our ﬁndings, previous studies
have shown that AA potentiates As2O3-mediated
cytotoxicity in U266 and multiple myeloma cells
[18,25]. The use of AA alone has a controversial
history in cancer treatment [26]. Cameron and
Pauling reported that AA or ascorbate, given in
pharmacologic doses of 10 g/day, is effective in
treating some cancers and improving patient well-
being [12]. One the contrary, Moertel and his
co-workers reported that the same dose of AA had
no effect on patient well-being and survival in two
double-blind placebo-controlled trials [27].
Ascorbic Acid Enhances Lipid Hydroperoxide
Generation in ArsenicTrioxide-treated HL-60 Cells
To investigate the hypothesis that ascorbic acid
(AA) enhances lipid hydroperoxide generation in
arsenic trioxide (As2O3)-treated cells. HL-60 cells
were exposed to different physiologic doses (25–
100 mM) of AA and a pharmacologic dose (6 mg/
mL) of As2O3 for 24 hours. Our results indicate
that the treatment of HL-60 cells with As2O3 alone
produces a signiﬁcantly higher level of lipid hydro-
peroxide, a major mediator of oxidative stress
and cellular injury that often leads to cell death.
This signiﬁcant increase in lipid hydroperoxide
concentrations was further exacerbated by AA
co-treatment. Based on these results, it is evident
that AA acts as a pro-oxidant in As2O3-treated
HL-60 cells. Our ﬁndings are in agreement with a
previous report indicating that AA exhibits pro-
oxidant activity in the presence of free transition
metals [28]. The relatively higher sensitivity of
0
2
4
6
8
10
12
14
16
Control 6A 25AA+6A 50AA+6A 100AA+6A
AA = Ascorbic Acid (µM),  A = Arsenic Trioxide (µg/mL)
L
i
p
i
d
 
H
y
d
r
o
p
e
r
o
x
i
d
e
 
(
µ
M
)
*
*
*
* *
Figure 2 AA potentiation on As2O3-induced oxidative
stress in HL-60 cells. Cells were incubated for 24 hr with
6 mg/mL As2O3 and various concentrations of AA (25, 50,
and 100 mM). Lipid hydroperoxide formation was deter-
mined as described in Materials and Methods. *Signiﬁ-
cantly different from the control by ANOVA Dunnett’s test;
P < 0.05. **Signiﬁcantly different from As2O3 alone by
ANOVA Dunnett’s test; P < 0.05. Data are representative of
3 independent experiments.
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related to its lower antioxidant defense and to the
presence of transition metals [29,30]. On the con-
trary, AA has an antioxidant effect in the absence of
metals, but becomes a pro-oxidant when they are
present [31,32]. Because AA potentiated As2O3-
mediated cell death, it is possible that As2O3 treat-
ment increased reactive oxygen species (ROS)
production. Consistent with this ﬁnding, pub-
lished reports indicate that arsenic induces the
generation of reactive oxygen species (ROS) that
contribute signiﬁcantly to cell killing [10,33].
Another study indicates that the cytotoxic and
genotoxic effects of As2O3 are mediated through
oxidative stress [7].
Figure 3 Representative ﬂow cytometry analysis data from Annexin V-FITC staining. The histogram shows a comparison
of the distribution of annexin V negative cells (M1) and annexin V positive cells (M2) after 24 h incubation in HL-60 cells.
A: control; B: 6 mg/mLAs2O3;C :2 5mMA A+ 6 mg/mLAs2O3;D :5 0mMA A+ 6 mg/mLAs2O3;E :1 0 0mMA A+ 6 mg/mLAs2O3.
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Figure 4 Annexin V-FITC positive cells induced by either
arsenic trioxide alone or ascorbic acid and arsenic trioxide
combination in HL-60 cells. Each point represents the
mean value and the standard deviation of three experi-
ments, showing similar results. *Signiﬁcantly different from
control (0 mg/mL), P < 0.05.
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Apoptosis in HL-60 Cells
Annexin-V is a speciﬁc phosphatidylserine-
binding protein used to detect apoptotic cells by
providing an assessment of the progression from
living cells (annexin-/PI-) towards apoptotic stage
(annexin+/PI-) and postapoptotic cell death
(annexin+/PI+). Our data show a progressive non-
signiﬁcant increase of apoptotic cells which reach
the highest value in the presence of AA and As2O3
(Figures 3 and 4). This ﬁnding was not statistically
signiﬁcant, but a limitation of the study was the
small number of experiments performed. Recent
literature has indicated that low concentrations of
As2O3 (2 mM) induces apoptosis in HPV 16 DNA-
immortalized human cervical epithelial cells and
that its molecular pathways leading to apoptosis
may be associated with down-regulation of viral
oncogene expression [34]. Others have reported
that As2O3 selectively induces acute promyelocytic
leukemia cell apoptosis via a hydrogen peroxide-
dependent pathway (10). Using the trypan blue
exclusion test and the ﬂow cytometry analysis, we
have shown in the present study that As2O3 causes
substantial cell death and apoptosis of HL-60 cells.
Administration of physiologic doses of AA was suf-
ﬁcient to enhance As2O3-induced cytotoxicity, oxi-
dative cell/tissue damage, and apoptosis of HL-60
cells. These ﬁndings highlight the potential effect
of AA in promoting the pharmacologic effect of
As2O3, suggesting a possible future role of AA/
As2O3 combination therapy in patients with APL.
Conclusions
Ascorbic acid (AA) and arsenic trioxide (As2O3)
co-treatment exerts dual effects on human leuke-
mia (HL-60) cells by inducing oxidative stress and
subsequent inhibition of cell growth and induction
of apoptosis. The trypan blue exclusion test results
indicated that AA and As2O3 combination signiﬁ-
cantly (P < 0.05) reduced cell viability of human
leukemia (HL-60) cells stronger than did As2O3
alone. Although the mechanism by which AA
enhances As2O3-mediated cytotoxicity in HL-60
cells remains unknown, here we provide evidence
that AA potentiates As2O3-induced toxicity through
oxidative cell/tissue damage and perhaps via apo-
ptosis in human leukemia (HL-60) cells. Based on
this knowledge, the elucidation of the synergy and
mechanisms of action between AA/As2O3 may
eventually lead to a more effective approach for
the management of patients with APL.
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